Published on in Vol 28 (2026)
Preprints (earlier versions) of this paper are
available at
https://preprints.jmir.org/preprint/78391, first published
.

Journals
- Shah E, AlShiab R, Abdo A, Ozbek L, Covic A, Kanbay M. Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP‐1 Receptor Agonists. Diabetes, Obesity and Metabolism 2026;28(6):4546 View
- Armanious A, Dunn A, Martin C, James M. Perceived effectiveness, tolerability, and discontinuation of lemborexant in real-world use: Evidence from online patient reports. Sleep Medicine 2027;149:109264 View
- Głodek K. SOCIAL PERCEPTION OF PHARMACOLOGICAL OBESITY TREATMENT IN THE ERA OF INCRETIN THERAPIES: AN ANALYSIS OF STIGMA IN MEDICAL AND NON-MEDICAL POPULATIONS. International Journal of Innovative Technologies in Social Science 2026;4(3(51)) View
